We’re experiencing technical issues with our homepage. Please use the menu or search to navigate the website while we resolve the issue. We apologise for the inconvenience.
SKYTROFA (Specialised Therapeutics Pharma Pty Ltd)
Product name
SKYTROFA
Date registered
Evaluation commenced
Decision date
Approval time
202 (255 working days)
Active ingredients
lonapegsomatropin
Registration type
NCE/NBE
Indication
Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion.